BookCedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammensee, editors.
Summary: This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
Contents:
Part I. Immunological and Regulatory Framework for Immuno-oncology
From Basic Immunology to New Therapies for Cancer Patients / Hans-Georg Rammensee
How T Cells Single Out Tumor Cells: "And That Has Made All the Difference...: / Marit M. van Buuren, Pia Kvistborg, and Ton N.M. Schumacher
Effects of Regulatory T Cell-Dendritic Cell Interactions on Adaptive Immune Responses / Tobias Bopp, Hans Christian Probst, Markus Radsak, Edgar Schmitt, Michael Stassen, Hansjörg Schild, and Stefan Tenzer
Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Cancer Vaccines / Cedrik Michael Britten, Thomas Hinz, Harpreet Singh-Jasuja, and Ulrich Kalinke
Immunoguiding, the Final Frontier in the Immunotherapy of Cancer / Sjoerd H. van der Burg, Steffen Walter, Sylvia Janetzki, Cedrik Michael Britten, Jérôme Galon, Marij J.P. Welters, and Cécile Gouttefangeas
Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress / Axel Hoos
Part II. Immunotherapies
Reflections on Cancer Vaccines / Cornelis J.M. Melief
Dendritic Cell-Based Cancer Vaccines / H. Westdorp, K.F. Bol, M. Coşkuntürk, G. Schreibelt, I.J.M. de Vries, and C.G. Figdor
mRNA Vaccination and Personalized Cancer Therapy / S. Kreiter, M. Diken, and U. Sahin
Antibody Therapy in Oncology / Martin Glennie, Özlem Türeci, and Peter W.M. Johnson
Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation / Gundram Jung and Ludger Grosse-Hovest
The ABCs of T Cell Receptor Gene Therapy / Dolores J. Schendel and Philip D. Greenberg
The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic / Hinrich Abken, Winfried S. Wels, and Klaus Kühlcke
Part III. Cancer Entities
Immunotherapy of Malignant Melanoma / Cedrik Michael Britten, G. Schuler, and S. Grabbe
Prostate Cancer Vaccines Generated with the Disruptive RNActive® Technology Follow the Path Paved by Sipuleucel-T and Prostvac-VF / Karl-Josef Kallen
Recent Developments in the Active Immunotherapy of Renal Cell Cancer / Harpreet Singh-Jasuja
Current Status of Immunotherapy in Gastroesophageal Cancer / Stefan Kasper and Martin Schuler
Non-small Cell Lung Cancer, NSCLC / Jens-Peter Marschner, Sonia Quaratino, and Ulf Forssmann
Towards More Specificity and Effectivity in the Antileukemia Immune Response / Udo F. Hartwig, Ralf G. Meyer, and Wolfgang Herr
Part IV. Biomarkers
Molecular and Metabolic Cues of the Key-Lock Paradigm Dictating Immunogenic Cell Death / Jonathan M. Pitt, Marie Vetizou, Oliver Kepp, Guido Kroemer, and Laurence Zitvogel
Pathogenesis of Minimal Residual Disease: CTCs as Novel Biomarkers in Cancer Disease / Tobias M. Gorges and Klaus Pantel
Genomics Meets Cancer Immunotherapy / John C. Castle, Sebastian Boegel, Thomas Bukur, Valesca Boisguerin, and Martin Loewer
Part V. Featured Chapters
Oncolytic Viruses / Michael D. Mühlebach and Stefan Hutzler
Part VI. Final Remarks
Final Words / Cedrik Michael Britten, Mustafa Diken, Sebastian Kreiter, and Hans-Georg Rammensee.